REG - ReNeuron Group plc - Appointment of Joint Broker

ReNeuronAnnouncement

25/02/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210225:nRSY2550Qa&default-theme=true

RNS Number : 2550Q  ReNeuron Group plc  25 February 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Appointment of Joint Broker

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
cell-based therapeutics, announces the appointment of Allenby Capital Limited
("Allenby") as joint corporate broker, with immediate effect to work alongside
the Company's existing nominated adviser and joint broker, Stifel Nicolaus
Europe Limited.

 

Michael Hunt, Chief Financial Officer of ReNeuron, commented: "The Company is
pleased to appoint Allenby as its joint corporate broker, which, together with
the appointment of Walbrook PR as the Company's new investor relations and PR
adviser, will further broaden our investor outreach activities, particularly
with regards to private client brokers and retail investors."

 

Contacts:

 

 ReNeuron                                                 www.reneuron.com/investors (http://www.reneuron.com/investors)
 Olav Hellebø, Chief Executive Officer                    Via Walbrook PR
 Michael Hunt, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)  +44 (0)20 7710 7600

 Ben Maddison, Stewart Wallace

 Allenby Capital Limited (Joint Broker)                   +44 (0)20 3328 5656

 James Reeve/George Payne (Corporate Finance)

 Tim Sohal (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                 +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus, Alice Woodings

                                                          +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique
stem cell technologies to develop 'off the shelf' stem cell treatments,
without the need for immunosuppressive drugs. The Company's lead cell therapy
candidate is in clinical development for the blindness-causing disease,
retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a
potential delivery system for drugs that treat diseases of the brain.  he
Company also has the ability through its conditionally immortalised induced
pluripotent stem cell (iPSC) platform to make any tissue cells of choice;
in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol
RENE.L.  For further information visit www.reneuron.com
(http://www.reneuron.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPQZLFLFLLEBBV